NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global Gene Therapy Market Analysis, Opportunities and Forecast 2024-2032

Global Gene Therapy market valued at USD 7.5B in 2023, projected to reach USD 40B by 2032 at 20.5% CAGR.

Revenue, 2023

$7.5B

Forecast, 2032

$40.2B

CAGR, 2024-2032

20.5%

Report Coverage

North America

Code: gene-therapy-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The global gene therapy market was USD 7.5 billion in 2023 and is projected to reach USD 40.2 billion by 2032, growing at a 20.5% CAGR. Key growth stems from rising oncology and rare disease applications, expanding CAR-T and AAV platforms, and increasing regulatory approvals. North America leads with 45% share, while Asia-Pacific exhibits the fastest growth. Investment opportunities are strong in vector manufacturing and next-generation delivery systems.

02

Key Highlights

1

Projected USD 40B market by 2032 at 20.5% CAGR.

2

North America holds 45% share; Asia‑Pacific fastest growth.

3

Oncology and rare disease segments drive majority of revenue.

03

Market Overview

Market Context

Gene therapy is rapidly evolving with increasing clinical successes, expanding indications, and improving manufacturing scalability, positioning it as a cornerstone of future precision medicine.

Gene therapy is a high-growth biotechnology segment driven by curative potential in oncology, rare genetic disorders, and cardiovascular diseases. The market is in an early‑adopter stage transitioning to mainstream adoption, with robust pipeline and improving reimbursement pathways.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Expansion of AAV and lentiviral vector platformsIncreasing FDA/EMA approvals for rare disease therapiesRise of in‑vivo gene editing (CRISPR‑Cas9) clinical trialsStrategic partnerships for manufacturing scale‑up
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 20.5%

Base Year (2023)

$7.5B

Forecast (2032)

$40.2B

CAGR (2024-2032)

20.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$7.50B
2024$9.04B
2025$10.89B
2026$13.12B
2027$15.81B
2028$19.05B
2029$22.96B
2030$27.67B
2031$33.34B
2032$40.17B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

Sustained double‑digit growth is expected as pipeline conversions, favorable reimbursement policies, and technological advances in vector delivery accelerate market adoption through 2032.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America45.0%18.0%United States
Europe30.0%20.0%Germany
Asia Pacific25.0%22.0%China

North America

#1
Share: 45.0%CAGR: 18.0%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 20.0%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • High unmet need in rare genetic disorders
  • Advancements in viral vector delivery
  • Favorable regulatory pathways for orphan drugs
06

Market Segmentation

By Type
Market share distribution across 2 segments
By Type — market share by segment, in percent.
SegmentShare
In‑vivo Gene TherapyDirect delivery of genetic material into patient cells, led by AAV and CRISPR platforms.60.0%
Ex‑vivo Gene TherapyCell modification outside the body, primarily CAR‑T and stem‑cell based therapies.40.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Application
Market share distribution across 4 segments
By Application — market share by segment, in percent.
SegmentShare
OncologyCAR‑T and tumor‑targeting gene edits dominate revenue.45.0%
Rare Genetic DisordersApproved therapies for spinal muscular atrophy, hemophilia, etc.30.0%
CardiovascularEmerging gene therapies for heart failure and familial hypercholesterolemia.15.0%
OtherIncludes ophthalmic, metabolic, and infectious disease applications.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Specialty Clinics
  • Research Institutes
07

Regional Analysis

1

North America

Lead: United States
CAGR: 18.0%Share: 45.0%

Dominant market due to advanced healthcare infrastructure and early adoption of CAR‑T therapies.

2

Europe

Lead: Germany
CAGR: 20.0%Share: 30.0%

Strong regulatory framework and growing investment in rare disease gene therapies.

3

Asia Pacific

Lead: China
CAGR: 22.0%Share: 25.0%

Fastest growth region driven by expanding biotech sector and increasing clinical trials.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
40.0%
+19.0%
Germany
12.0%
+18.0%
China
10.0%
+24.0%
08

Competitive Landscape

N

Novartis

Switzerland

Leader50B

Pioneer in CAR‑T therapy with Kymriah and strong pipeline in AAV‑based gene therapies.

Global pharma leader with approved CAR‑T therapy Kymriah and expanding AAV pipeline.

b

bluebird bio

United States

Challenger1B

Focused on lentiviral gene therapies for rare diseases, highlighted by Zynteglo and Skysona.

Specialist in lentiviral gene therapies for rare diseases, with Zynteglo and Skysona on market.

P

Pfizer

United States

Follower60B

Expanding gene therapy portfolio through acquisitions and internal R&D, notably with rare disease programs.

Large‑scale pharma with a growing gene therapy portfolio through acquisitions and internal programs.

09

Recent Developments

25
2025CRISPR Therapeutics

Initiated Phase III trial for CTX001 in sickle cell disease.

24
2024Novartis

Received EMA approval for next‑generation AAV‑based spinal muscular atrophy therapy.

10

Regulatory Landscape

FDA’s RMAT designation accelerating gene therapy approvalsEMA’s Adaptive Pathways for early access to innovative gene therapies
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

Focus on companies with diversified gene therapy platforms and strong regulatory pipelines.

Operators

Invest in manufacturing capacity and strategic partnerships to meet rising demand.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.